Author: Zacks Equity Research

EYE – National Vision (EYE) Surpasses Q1 Earnings and Revenue Estimates

Written by Zacks Equity Research on . Posted in EYE, Stock Report.

National Vision (EYE – Free Report) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.28 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 45.45%. A quarter ago, it was expected that this discount optical retailer and eye care provider would post earnings of $0.13 per share when it actually produced earnings of $0.45, delivering a surprise of 246.15%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

National Vision, which belongs to the Zacks Medical – Products industry, posted revenues of $534.18 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 3.14%. This compares to year-ago revenues of $469.7 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.

National Vision shares have added about 3.6% since the beginning of the year versus the S&P 500’s gain of 8.2%.

What’s Next for National Vision?

While National Vision has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for National Vision was favorable. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.20 on $472.3 million in revenues for the coming quarter and $0.90 on $1.97 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical – Products is currently in the bottom 25% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

FLUX – Flux Power Holdings, Inc. (FLUX) Reports Q3 Loss, Tops Revenue Estimates

Written by Zacks Equity Research on . Posted in FLUX, Stock Report.

Flux Power Holdings, Inc. (FLUX – Free Report) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.78 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 39.13%. A quarter ago, it was expected that this company would post a loss of $0.27 per share when it actually produced a loss of $0.29, delivering a surprise of -7.41%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Flux Power Holdings, Inc.Which belongs to the Zacks Electronics – Miscellaneous Products industry, posted revenues of $6.96 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 14.16%. This compares to year-ago revenues of $5.05 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.

Flux Power Holdings, Inc. Shares have lost about 55.4% since the beginning of the year versus the S&P 500’s gain of 8.2%.

What’s Next for Flux Power Holdings, Inc.

While Flux Power Holdings, Inc. Has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Flux Power Holdings, Inc. Was mixed. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.19 on $7.3 million in revenues for the coming quarter and -$1.10 on $24.3 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Electronics – Miscellaneous Products is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

FREQ – Frequency Therapeutics, Inc. (FREQ) Reports Q1 Loss, Misses Revenue Estimates

Written by Zacks Equity Research on . Posted in FREQ, Stock Report.

Frequency Therapeutics, Inc. (FREQ – Free Report) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -122.22%. A quarter ago, it was expected that this company would post a loss of $0.30 per share when it actually produced a loss of $0.30, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Frequency Therapeutics, Inc.Which belongs to the Zacks Medical – Biomedical and Genetics industry, posted revenues of $4.65 million for the quarter ended March 2021, missing the Zacks Consensus Estimate by 41.86%. This compares to year-ago revenues of $7.26 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.

Frequency Therapeutics, Inc. Shares have lost about 71.4% since the beginning of the year versus the S&P 500’s gain of 8.2%.

What’s Next for Frequency Therapeutics, Inc.

While Frequency Therapeutics, Inc. Has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Frequency Therapeutics, Inc. Was unfavorable. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.30 on $8 million in revenues for the coming quarter and -$0.17 on $69.19 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical – Biomedical and Genetics is currently in the bottom 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

FPI – Farmland Partners (FPI) Reports Q1 Loss, Tops Revenue Estimates

Written by Zacks Equity Research on . Posted in FPI, Stock Report.

Farmland Partners (FPI – Free Report) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an FFO surprise of -150%. A quarter ago, it was expected that this real estate investment trust specializing in farmland would post FFO of $0.33 per share when it actually produced FFO of $0.16, delivering a surprise of -51.52%.

Over the last four quarters, the company has not been able to surpass consensus FFO estimates.

Farmland Partners, which belongs to the Zacks REIT and Equity Trust – Other industry, posted revenues of $11.58 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 15.83%. This compares to year-ago revenues of $11.65 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock’s immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management’s commentary on the earnings call.

Farmland Partners shares have added about 51.7% since the beginning of the year versus the S&P 500’s gain of 8.2%.

What’s Next for Farmland Partners?

While Farmland Partners has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Farmland Partners was unfavorable. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #5 (Strong Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus FFO estimate is -$0.04 on $10.26 million in revenues for the coming quarter and $0.19 on $54.12 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust – Other is currently in the bottom 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

HAE – Haemonetics (HAE) Q4 Earnings and Revenues Miss Estimates

Written by Zacks Equity Research on . Posted in HAE, Stock Report.

Haemonetics (HAE – Free Report) came out with quarterly earnings of $0.46 per share, missing the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $0.69 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -31.34%. A quarter ago, it was expected that this provider blood management systems for health care providers and blood collectors would post earnings of $0.68 per share when it actually produced earnings of $0.81, delivering a surprise of 19.12%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Haemonetics, which belongs to the Zacks Medical – Products industry, posted revenues of $225.03 million for the quarter ended March 2021, missing the Zacks Consensus Estimate by 0.06%. This compares to year-ago revenues of $238.49 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.

Haemonetics shares have lost about 49.6% since the beginning of the year versus the S&P 500’s gain of 8.2%.

What’s Next for Haemonetics?

While Haemonetics has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Haemonetics was unfavorable. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.76 on $237.9 million in revenues for the coming quarter and $3.57 on $1.01 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical – Products is currently in the bottom 25% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

LQDA – Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates

Written by Zacks Equity Research on . Posted in LQDA, Stock Report.

Liquidia Technologies, Inc. (LQDA – Free Report) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.52 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -5%. A quarter ago, it was expected that this company would post a loss of $0.38 per share when it actually produced a loss of $0.38, delivering no surprise.

Over the last four quarters, the company has not been able to surpass consensus EPS estimates.

Liquidia Technologies, Inc.Which belongs to the Zacks Medical – Biomedical and Genetics industry, posted revenues of $3.08 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 260.28%. This compares to zero revenues a year ago.

The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.

Liquidia Technologies, Inc. Shares have lost about 7.1% since the beginning of the year versus the S&P 500’s gain of 8.2%.

What’s Next for Liquidia Technologies, Inc.

While Liquidia Technologies, Inc. Has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Liquidia Technologies, Inc. Was mixed. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.21 on $0.96 million in revenues for the coming quarter and -$0.81 on $3.87 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical – Biomedical and Genetics is currently in the bottom 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

PGTI – PGT (PGTI) Q1 Earnings and Revenues Top Estimates

Written by Zacks Equity Research on . Posted in PGTI, Stock Report.

PGT (PGTI – Free Report) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.28 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 42.11%. A quarter ago, it was expected that this maker of windows and doors would post earnings of $0.16 per share when it actually produced earnings of $0.18, delivering a surprise of 12.50%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

PGT, which belongs to the Zacks Building Products – Miscellaneous industry, posted revenues of $271.09 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 7.09%. This compares to year-ago revenues of $220.2 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.

PGT shares have added about 18.5% since the beginning of the year versus the S&P 500’s gain of 8.2%.

What’s Next for PGT?

While PGT has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for PGT was mixed. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.29 on $260.34 million in revenues for the coming quarter and $1.18 on $1.05 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Building Products – Miscellaneous is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

GOEV – Canoo (GOEV) Gears up for Q1 Earnings: What's in the Offing?

Written by Zacks Equity Research on . Posted in GOEV, Stock Report.

Canoo Inc. (GOEV – Free Report) is slated to release first-quarter 2021 results on May 17. The electric vehicle (EV) startup made NASDAQ debut on Dec 22, 2020 by merging with a special purpose acquisition company, Hennessy Capital Acquisition. The Zacks Consensus Estimate for first-quarter loss of 23 cents per share has narrowed by 2 cents over the past 30 days.

In the last reported quarter, the company incurred a loss of 66 cents a share, wider than the Zacks Consensus Estimate of loss of 14 cents. Canoo didn’t generate any revenues in the fourth quarter of 2020. The Zacks Consensus Estimate for the same was $3 million.

Earnings Whispers

Our proven model predicts an earnings beat for Canoo this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. You can see the complete list of today’s Zacks #1 Rank stocks here.

Canoo — whose peers include Nikola (NKLA – Free Report) , ElectraMeccanica (SOLO – Free Report) and Arcimoto (FUV – Free Report) — has an Earnings ESP of +8.70% and a Zacks Rank #3.

Factors to Note

For starters, investors should note that Canoo is still in the nascent stages of development, without any single vehicle officially launched yet. The company is currently not generating any revenues but its proprietary technology platform, and plans of offering subscription services as well as licensing the platform to other EV makers are likely to boost first-quarter 2021 results.

During the March-end quarter, Canoo unveiled its fully-electric pickup truck. It is looking to make its first vehicle available via an all-inclusive subscription fee and is also likely to consider licensing its platform to other original equipment manufacturers. These factors are likely to have sparked optimism regarding the company’s future and are expected to benefit first-quarter results.

Nonetheless, it is likely to have felt the heat from rising operating expenses and high capex to develop these technically advanced vehicles, which may have marred first-quarter 2021 margins. Notably, Canoo expects first-quarter 2021 operating expenses in the band of $45-$50 million and capex of $10-$12 million.

Zacks’ Top Picks to Cash in on Artificial Intelligence

In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create “the world’s first trillionaires.” Zacks’ urgent special report reveals 3 AI picks investors need to know about today.

See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>

MTDR – Matador Resources (MTDR) Q1 Earnings and Revenues Surpass Estimates

Written by Zacks Equity Research on . Posted in MTDR, Stock Report.

Matador Resources (MTDR – Free Report) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.20 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 82.05%. A quarter ago, it was expected that this independent oil and gas company would post earnings of $0.12 per share when it actually produced earnings of $0.27, delivering a surprise of 125%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Matador, which belongs to the Zacks Oil and Gas – Exploration and Production – United States industry, posted revenues of $266.85 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 0.09%. This compares to year-ago revenues of $371.59 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.

Matador shares have added about 106.4% since the beginning of the year versus the S&P 500’s gain of 11.5%.

What’s Next for Matador?

While Matador has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Matador was favorable. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.59 on $324.96 million in revenues for the coming quarter and $2.47 on $1.25 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Oil and Gas – Exploration and Production – United States is currently in the top 21% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

VSTO – Vista Outdoor (VSTO) Dips More Than Broader Markets: What You Should Know

Written by Zacks Equity Research on . Posted in Stock Report, VSTO.

In the latest trading session, Vista Outdoor (VSTO – Free Report) closed at $32.60, marking a -1.66% move from the previous day. This change lagged the S&P 500’s daily loss of 0.09%.

Coming into today, shares of the maker of firearms, ammunition and accessories had gained 8.09% in the past month. In that same time, the Consumer Discretionary sector gained 0.75%, while the S&P 500 gained 5.45%.

VSTO will be looking to display strength as it nears its next earnings release, which is expected to be May 6, 2021. The company is expected to report EPS of $0.64, up 481.82% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $530.79 million, up 24.51% from the prior-year quarter.

Any recent changes to analyst estimates for VSTO should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company’s business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.18% higher. VSTO is currently a Zacks Rank #3 (Hold).

Looking at its valuation, VSTO is holding a Forward P/E ratio of 11.91. This valuation marks a discount compared to its industry’s average Forward P/E of 15.25.

The Leisure and Recreation Products industry is part of the Consumer Discretionary sector. This group has a Zacks Industry Rank of 41, putting it in the top 17% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

Copyright 2010. Elite Stock Chat. All Rights Reserved